[go: up one dir, main page]

PE20050870A1 - Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion - Google Patents

Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion

Info

Publication number
PE20050870A1
PE20050870A1 PE2004000799A PE2004000799A PE20050870A1 PE 20050870 A1 PE20050870 A1 PE 20050870A1 PE 2004000799 A PE2004000799 A PE 2004000799A PE 2004000799 A PE2004000799 A PE 2004000799A PE 20050870 A1 PE20050870 A1 PE 20050870A1
Authority
PE
Peru
Prior art keywords
water
acetone
solution
dimetoxy
docetaxel
Prior art date
Application number
PE2004000799A
Other languages
English (en)
Inventor
Eric Didier
Marc-Antoine Perrin
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050870(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20050870A1 publication Critical patent/PE20050870A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE REFIERE AL SOLVATO ACETONICO DEL DIMETOXI DOCETAXEL O (2R,3S)-3-TERC-BUTOXICARBONIL-AMINO-2-HIDROXI-3-FENILPROPIONATO DE 4-ACETOXI-2a-BENZOIL-OXI-5ß, 20-EPOXI-1-HIDROXI-7ß, 10ß-DIMETOXI-9-OXO-TAX-11-ENO-13a-ILO Y AL SU PREPARACION POR CRISTALIZACION A PARTIR DE UNA SOLUCION HIDRO-ALCOHOLICA, ESTE PROCESO COMPRENDE: a) PONER EN SOLUCION EL COMPUESTO EN ACETONA b) TRATAR LA SOLUCION CON AGUA, c) SEMBRAR LA SOLUCION CON UNA SUSPENCION DE DICHO PRODUCTO EN UNA MEZCLA DE ACETONA/AGUA, LA CONCENTRACION DE LA SIEMBRA ES DE 60 A 80 g/L DE MEZCLA QUE CONTIENE UN RATIO VOLUMETRICO ACETONA/AGUA ENTRE 65/35 A 75/25, EL CUAL ES TRATADO DENUEVO CON AGUA, EN DONDE LA CONCENTRACION FINAL ACETONA/AGUA ESTA COMPRENDIDA ENTRE 70/30 COMO MINIMO Y 30/70 COMO MAXIMO. ESTE PROCESO SE DESARROLLA A UNA TEMPERATURA DE 20 ± 5°C, d) SEPARACION DE LOS CRISTALES OBTENIDOS Y e) SECADO BAJO PRESION A UNA TEMPERATURA ENTRE 30 Y 60°C BAJO UNA PRESION PROXIMA 0,7 kPA. EL COMPUESTO PRESENTA PROPIEDADES ANTICANCEROSAS Y ANTILEUCEMICAS
PE2004000799A 2003-09-19 2004-08-19 Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion PE20050870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (1)

Publication Number Publication Date
PE20050870A1 true PE20050870A1 (es) 2005-11-21

Family

ID=34224354

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000799A PE20050870A1 (es) 2003-09-19 2004-08-19 Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion

Country Status (37)

Country Link
US (1) US7241907B2 (es)
EP (1) EP1667986B1 (es)
JP (1) JP5010279B2 (es)
KR (1) KR101123588B1 (es)
CN (1) CN100429207C (es)
AR (1) AR045667A1 (es)
AU (1) AU2004274212B2 (es)
BE (1) BE2013C036I2 (es)
BR (1) BRPI0414492A8 (es)
CA (1) CA2539309A1 (es)
CR (1) CR8292A (es)
CY (2) CY1114575T1 (es)
DK (1) DK1667986T3 (es)
ES (1) ES2403149T4 (es)
FR (2) FR2859996B1 (es)
HR (1) HRP20130322T1 (es)
HU (1) HUS1300025I1 (es)
IL (1) IL174240A (es)
LU (1) LU92172I2 (es)
MA (1) MA28045A1 (es)
ME (2) ME00054B (es)
MX (1) MXPA06002639A (es)
MY (1) MY136668A (es)
NO (2) NO335997B1 (es)
NZ (1) NZ545835A (es)
PA (1) PA8612401A1 (es)
PE (1) PE20050870A1 (es)
PL (1) PL1667986T3 (es)
PT (1) PT1667986E (es)
RS (2) RS54614B1 (es)
RU (1) RU2342373C2 (es)
SI (1) SI1667986T1 (es)
TN (1) TNSN06086A1 (es)
TW (1) TWI382022B (es)
UA (1) UA87115C2 (es)
WO (1) WO2005028462A1 (es)
ZA (1) ZA200602255B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109654A2 (en) * 2006-03-21 2007-09-27 Dr. Reddy's Laboratories Ltd. Docetaxel polymorphs and processes
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス, インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
JP5566466B2 (ja) 2009-10-29 2014-08-06 アバンテイス・フアルマ・エス・アー カバジタキセルの新規の抗腫瘍的使用
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
KR20140018917A (ko) * 2011-04-12 2014-02-13 플러스 케미칼스, 에스.에이. 카바지탁셀의 고상 형태 및 이의 제조 방법
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
WO2013072766A2 (en) 2011-10-31 2013-05-23 Scinopharm Taiwan, Ltd. Process for cabazitaxel and intermediates thereof
EP2773629B1 (en) 2011-11-01 2018-04-11 Fresenius Kabi Oncology Limited Process for the preparation of an amorphous form of cabazitaxel
PL2785701T3 (pl) * 2011-11-28 2019-08-30 Fresenius Kabi Oncology Limited Krystaliczna postać kabazytakselu i sposób jej otrzymywania
WO2013088335A1 (en) 2011-12-13 2013-06-20 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
CA2864029A1 (en) * 2012-02-10 2013-08-15 Aventis Pharma S.A. New pediatric uses of cabazitaxel
WO2013134534A2 (en) 2012-03-08 2013-09-12 Plus Chemicals S.A. Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
WO2014022237A1 (en) 2012-07-31 2014-02-06 Yung Shin Pharm. Ind. Co., Ltd. Amorphous cabazitaxel
EP2884963B1 (en) 2012-08-15 2017-12-27 Yung Shin Pharm. Ind. Co. Ltd. Stable pharmaceutical formulation of cabazitaxel
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865675A1 (en) * 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
US20180311203A1 (en) 2015-01-12 2018-11-01 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
EP3258931B1 (en) * 2015-02-17 2020-08-12 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
DE4425978C1 (de) * 1994-07-22 1995-11-23 Karlsruhe Forschzent Verfahren zur Herstellung keramischer Mikrostrukturen
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
HUP0201176A3 (en) * 1999-05-17 2005-02-28 Bristol Myers Squibb Co Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel taxol and their analogues
CN1295229C (zh) * 2001-11-29 2007-01-17 第一制药株式会社 紫杉烷衍生物的结晶及其制备方法

Also Published As

Publication number Publication date
NO20061714L (no) 2006-04-19
IL174240A0 (en) 2006-08-01
AR045667A1 (es) 2005-11-02
FR2859996A1 (fr) 2005-03-25
HK1093340A1 (zh) 2007-03-02
EP1667986A1 (fr) 2006-06-14
RS20060189A (sr) 2008-06-05
BE2013C036I2 (es) 2023-12-14
CN1849311A (zh) 2006-10-18
CY2013016I2 (el) 2018-01-10
MEP11708A (en) 2010-06-10
NO2015013I1 (no) 2015-05-04
NO335997B1 (no) 2015-04-20
UA87115C2 (ru) 2009-06-25
DK1667986T3 (da) 2013-05-06
MXPA06002639A (es) 2006-06-05
IL174240A (en) 2010-12-30
KR101123588B1 (ko) 2012-03-22
ZA200602255B (en) 2007-07-25
MY136668A (en) 2008-11-28
TW200524891A (en) 2005-08-01
EP1667986B1 (fr) 2013-01-16
KR20060072147A (ko) 2006-06-27
NO2015013I2 (no) 2015-04-22
PL1667986T3 (pl) 2013-06-28
FR13C0037I2 (fr) 2015-11-20
ME00054B (me) 2011-02-10
TWI382022B (zh) 2013-01-11
AU2004274212A1 (en) 2005-03-31
ES2403149T3 (es) 2013-05-14
AU2004274212B2 (en) 2010-03-04
US7241907B2 (en) 2007-07-10
SI1667986T1 (sl) 2013-05-31
PA8612401A1 (es) 2005-08-04
FR13C0037I1 (fr) 2013-09-08
TNSN06086A1 (en) 2007-10-03
BRPI0414492A (pt) 2006-11-14
BRPI0414492A8 (pt) 2019-01-15
WO2005028462A1 (fr) 2005-03-31
US20050065138A1 (en) 2005-03-24
NZ545835A (en) 2009-10-30
JP5010279B2 (ja) 2012-08-29
PT1667986E (pt) 2013-04-24
CA2539309A1 (fr) 2005-03-31
RU2006113122A (ru) 2006-08-27
CN100429207C (zh) 2008-10-29
LU92172I2 (fr) 2013-05-21
MA28045A1 (fr) 2006-07-03
HUS1300025I1 (hu) 2016-08-29
ES2403149T4 (es) 2013-06-24
CY1114575T1 (el) 2016-10-05
LU92172I9 (es) 2019-01-03
RS54614B1 (sr) 2016-08-31
CY2013016I1 (el) 2018-01-10
HRP20130322T1 (en) 2013-07-31
FR2859996B1 (fr) 2006-02-03
RU2342373C2 (ru) 2008-12-27
CR8292A (es) 2008-10-15
JP2007505866A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
PE20050870A1 (es) Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion
BR112018067520A2 (pt) recipiente de substâncias hidropônicas flexível
MX2007010359A (es) Trans carotenoides, su sintesis, formulacion y usos.
NZ589228A (en) Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) for the treatment of a brain tumour
PE20070244A1 (es) Biotejido de colageno derivado de placenta para el tratamiento de ulceras en la pierna
ATE401882T1 (de) Antikrebszubereitung enthaltend dmxaa
BRPI0408388A (pt) compostos de benzopirano úteis no tratamento de patologias inflamatórias
EP2502906A3 (de) Trypsinartige Serinprotease-Hemmstoffe, ihre Herstellung und Verwendung
CO6150099A2 (es) Agente de mejoramiento de fermentacion del rumen
EA201001283A1 (ru) Комбинация витамина d и 25-гидроксивитамина d3
AR064812A1 (es) Proceso para el tratamiento de sulfato de calcio hemihidratado beta y producto obtenido
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
NO20074318L (no) Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer
CL2004001409A1 (es) Compuestos derivados de heterociclos biciclicos, sus sales; composicion farmaceutica; procedimientos de preparacion; y su uso para preparar un medicamento para tratar tumores, enfermedades de las vias respiratorias y del pulmon, del tracto gastrointe
MX2024009117A (es) Inhibidores de hsd17b13 sustituidos con 2 tiazoles y usos de los mismos
EP1759715A4 (en) STERILIZATION SYSTEM
BR112012032385A2 (pt) método e aparelho de banho de pressão de névoa de gás de dióxido de carbono
EA200501639A1 (ru) Дифторметилбензанилиды и их применение для борьбы с микроорганизмами, промежуточные соединения и их получение
BRPI0411966A (pt) formas cristalinas de perindopril erbumina
CN103275090A (zh) 一种酶法水解结合闪式提取快速从松针中提取脂溶性叶绿素的方法
AR064569A1 (es) Legumbres con alto contenido de zinc
ATE443451T1 (de) Eiskonfekt
Cheragh et al. Effect of Tetraselmis suecica microalgae isolated from the Persian Gulf on the expression level of AKT/mTOR genes in the liver cancer cell line, Huh7
PH12020550884A1 (en) Anisotropic nanoparticle compositions and methods

Legal Events

Date Code Title Description
FC Refusal